Etoposide

규격

33419-42-0CAS 번호

251-509-1EC 번호

(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-oneIUPAC 명칭

C29H32O13화학식

588.6 g/mol분자량

etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; (-)-Etoposide; Lastet; Etoposido; Etoposidum; Eposin; Sintopozid; VP-16-213; VP 16-213; NSC-141540; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16; EPEG; DTXSID5023035; VP 16213; 6PLQ3CP4P3; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); NSC 141540; CHEBI:4911; DTXCID601473876; Eposide; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one-, 9-((4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl), (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-; NSC141540; (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one; Etoposide Teva; Teva, Etoposide; alpha-D-Glucopyranosyl Isomer Etoposide; (10R,11R,15R,16S)-16-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano(3,2-d)(1,3)dioxin-6-yl)oxy)-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo(7.7.0.0^(3,7).0^(11,15))hexadeca-1(9),2,7-trien-12-one; (5S,5aR,8aR,9R)-5-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano(3,2-d)(1,3)dioxin-6-yl)oxy)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-(2)benzofuro(6,5-f)(1,3)benzodioxol-8-one; Eto GRY; RefChem:56691; Demethyl Epipodophyllotoxin Ethylidine Glucoside; L01CB01; Etoposide, alpha D Glucopyranosyl; VP 16 213; (10R,11R,15R,16S)-16-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano(3,2-d)(1,3)dioxin-6-yl)oxy)-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo(7.7.0.03,7.011,15)hexadeca-1,3(7),8-trien-12-one; (5R,5aR,8aR,9S)-9-((4,6-O-(1R)-Ethylidene-beta-D-glucopyranosyl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro(3',4':6,7)naphtho(2,3-d)(1,3)dioxol-6(5aH)-one; 251-509-1; 9-((4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one; Zuyeyidal; VP-16; Etoposidum [INN-Latin]; Etoposide (VP16); Vepesid J; VP 16 (pharmaceutical); Epipodophyllotoxin VP-16213; CHEMBL44657; NK 171; Etoposide (VP-16); Etosid; C29H32O13; Etoposido [INN-Spanish]; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; Etopophos (phosphate salt); Etopol; (5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; SMR000112002; ol-6(8H)-one; CCRIS 2392; HSDB 6517; VePESID (TN); EINECS 251-509-1; UNII-6PLQ3CP4P3; 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside; Vespid; Etopophos;; Abiposid;; Vepeside;; Amizide;; Citodox;; Toposar;; Vepesid;; Etoposide CRS; Exitop;; NCGC00016821-01; (5R,5aR,8aR,9S)-9-(((4aR,6R,7R,8R,8aS)-7,8-Dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; EVP; Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-; Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); CAS-33419-42-0; AVOPEF; Etoposide (Standard); Etoposide [USAN:USP:INN:BAN:JAN]; Etoposide; VP-16; CPD000112002; Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-; ETOPOSIDE [INN]; ETOPOSIDE [JAN]; ETOPOSIDE [MI]; ETOPOSIDE [HSDB]; ETOPOSIDE [IARC]; ETOPOSIDE [USAN]; Prestwick3_000396; ETOPOSIDE [VANDF]; ETOPOSIDE [MART.]; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; ETOPOSIDE [USP-RS]; ETOPOSIDE [WHO-DD]; ETOPOSIDE [WHO-IP]; SCHEMBL4259; BSPBio_000611; 9-((4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4- hydroxy-3,4-dimethyloxyphenyl)furo (3',4'':6,7) naptho-(2,3-d)-1,3-dioxol-6 (5aH)-one; MLS000049957; MLS001074951; MLS001424283; MLS002153463; MLS002207239; MLS002222184; Etoposide - Bio-X trade mark; Etoposide (JP18/USP/INN); BPBio1_000673; GTPL6815; orb1310906; orb3141266; ETOPOSIDE [EP IMPURITY]; ETOPOSIDE [ORANGE BOOK]; ETOPOSIDE [EP MONOGRAPH]; ETOPOSIDE [USP IMPURITY]; SCHEMBL29653657; ETOPOSIDE [USP MONOGRAPH]; ETOPOSIDUM [WHO-IP LATIN]; HMS2052N05; HMS2089F14; HMS2096O13; HMS2232L03; HMS3713O13; HMS6018O17; EX-A1207; Tox21_110630; Tox21_302201; BDBM50127140; EBC-11154; Etoposide for system suitability CRS; HY-13629R; MSK001347; s1225; AKOS007930275; CCG-101165; CS-1774; DB00773; Etoposide, synthetic, >=98%, powder; ME09941; NC00415; SDCCGSBI-0050405.P002; 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; NCGC00179504-02; NCGC00179504-30; NCGC00255126-01; AS-35312; BE164434; HY-13629; SBI-0051910.P002; AB00438905; E7657; NS00009585; T0132; EN300-97099; C01576; D00125; AB00438905-17; AB00438905-18; AB00438905_19; Q418817; SR-01000763196; SR-01000763196-3; BRD-K37798499-001-02-5; BRD-K37798499-001-05-8; BRD-K37798499-001-10-8; BRD-K37798499-001-14-0; BRD-K37798499-001-18-1; BRD-K37798499-001-21-5; BRD-K37798499-001-22-3; BRD-K37798499-001-25-6; BRD-K37798499-001-27-2; -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; Etoposide, British Pharmacopoeia (BP) Reference Standard; Z1304065033; Etoposide, European Pharmacopoeia (EP) Reference Standard; Etoposide, United States Pharmacopeia (USP) Reference Standard; 4?-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-b-D-glucopyranoside); 4''-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSIDE); Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard; (5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]diox; (5R,5AR,8AR,9S)-9-((4,6-O-((1R)-ETHANE-1,1-DIYL)-.ALPHA.-D-GLUCOPYRANOSYL)OXY)-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDRO(2)BENZOFURO(5,6-F)(1,3)BENZODIOXOL-6(5AH)-ONE; (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-|_-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[5,6-f][1,3]benzodioxol-8-one; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one; (5S,5aR,8aR,9R)-9-(4-Hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3'',4'':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; 121471-01-0; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3'',4'''':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE-, 9-((4,6-O-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSYL)OXY)5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL), (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.BETA.(R*)))-동의어